Global Allergy Immunotherapy Market to Grow at a CAGR of 9.6% During the Period 2024-2032, Driven by Growing Prevalence of Allergic Diseases

Allergen immunotherapy refers to the repeated administration of allergen extracts to allergic individuals to offer long-term relief of symptoms and improvement in quality of life during succeeding natural allergen exposure. Allergen immunotherapy is effective in IgE-mediated disease in patients with a limited spectrum (1 or 2) of allergies. In the USA, over 7.5% of the people eighteen years of age or above experience allergic rhinitis or hay fever. A significant percentage of children also suffers from hay fever. Allergic rhinitis affects ten to thirty percent of the population across the globe. Further, over five percent of children across the world experience some kind of food allergy. Globally, increase in prevalence of allergic diseases has continued in the industrialized world for over fifty years. Such prevalence of allergic conditions is expected to drive the global allergy immunotherapy market. North America, Europe and Asia Pacific are likely to be key markets.

Key Developments

In 2019, Adamis Pharmaceuticals Corporation announced that its marketing and commercial partner, Sandoz Inc. (Sandoz) had launched SYMJEPI™ (epinephrine) 0.3 mg Injection in the US market for the emergency treatment of allergic reactions (Type 1), including anaphylaxis. Sandoz launched the medicine as a reasonably priced, single-dose, pre-filled syringe alternative to epinephrine auto-injectors. Such developments are expected to boost the global allergy immunotherapy market.

In 2022, a study showed no evidence that women felt adverse events in their pregnancies if they had been treated with allergen-specific immunotherapy (AIT) three months before conception up to gestational week 22.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

In 2022, a clinical trial funded by the National Institutes of Health revealed that giving peanut oral immunotherapy to highly peanut-allergic children aged 1 to 3 years safely desensitized majority of them to peanut and brought about remission of peanut allergy in one-fifth. The results of the IMPACT trial suggested a window of opportunity in early childhood to induce remission of peanut allergy through oral immunotherapy. It is noteworthy that peanut allergy affects nearly two percent of the children in USA, or about 1.5 million individuals aged 17 years and younger. The risk of a life-threatening allergic reaction to accidentally eaten peanut was significant for these children, most of which remain peanut-allergic for life.

Key Findings of the Report:

• Rising incidence of allergic conditions across the world is expected to drive the global allergy immunotherapy market.

• Advances in research are likely to stimulate market growth.

• North America, Europe and Asia are projected to be key markets.

Market Analysis by Allergy, Treatment, Distribution Channel and Region:

• By allergy, the market is segmented into Allergic Asthma, Cat Allergy, Allergic Rhinitis, Peanut Allergy, and Others.

• By treatment, the market is divided into Sublingual Immunotherapy, Subcutaneous Immunotherapy (SCIT), and Specific Immunotherapy (SIT).

• By distribution channel, the market is classified into Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy.

• By region, the market is segmented into: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us

Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790